You are here: Industry Insights > Imfinzi

News List

AstraZeneca, AVEO Oncology form lung cancer collaboration pharmatimes
December 13, 2018
AVEO Oncology has announced the start of an immuno-oncology focused clinical collaboration with drug giant AstraZeneca (AZ).
AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study expressbpd
December 11, 2018
The study, known as ‘EAGLE’, did not improve overall survival compared with standard chemotherapy in patients with the hard-to-treat disease
AZ’s cancer drug fails again, Roche’s rival gets new use pharmaphorum
December 10, 2018
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication.
AstraZeneca Provides Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in Advanced Head and Neck Cancer americanpharmaceuticalreview
December 10, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised....
AZ’ Imfinzi fails in head and neck cancer trial pharmatimes
December 10, 2018
AstraZeneca and MedImmune’s Imfinzi has failed to hit targets in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Setback for AZ’ Imfinzi lung cancer combination pharmatimes
November 20, 2018
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
AstraZeneca’s Imfinzi alone and in combination fails in Stage IV lung cancer trial pharmaceutical-technology
November 19, 2018
AstraZeneca has announced its Phase III MYSTIC trial of Imfinzi alone and Imfinzi combined with tremelimumab in untreated non-small cell lung cancer (NSCLC) patients failed to meet its primary endpoint.
Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer firstwordpharma
November 09, 2018
Phase 2 Platform Study to Evaluate the Combination of Imfinzi® (Durvalumab) and Sacituzumab Govitecan in Patients with Non-Small Cell Lung Cancer Who Progressed
AZ’ Imfinzi reduces risk of death by 32% in stage III NSCLC pharmatimes
September 27, 2018
AstraZeneca says Imfinzi is the first immunotherapy to show significant overall survival in a curative lung cancer treatment setting.
EU approves AstraZeneca immunotherapy drug for lung cancer expressbpd
September 26, 2018
The green light from the EU had been expected following a positive recommendation from experts at the European Medicines Agency

Previous page 1 2 3 4 5 Next page